Navigation Links
Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
Date:3/19/2008

MELBOURNE, Australia, March 19 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has received ethics approval to commence treating patients with Type 1 diabetes in a Phase 2 clinical trial using its patented transdermal insulin delivery system, TPM/Insulin. The lead clinical investigators of the trial will be Dr. Michael D' Emden, Department of Endocrinology, Royal Brisbane and Women's Hospital, and William Hsu, who is an Assistant Investigator in the Section on Clinical Research at the Joslin Diabetes Centre and an Assistant Professor of Medicine at Harvard Medical School, Boston, MA.

Ethics approval was granted on the basis of data generated from previous trials and the first arm of the Phase 2 trial, which involves the treatment of patients with Type 2 diabetes. Phosphagenics had to demonstrate safety and the effective delivery of insulin into the bloodstream of patients with Type 2 diabetes prior to receiving ethics approval to commence a trial for patients with Type 1 diabetes.

The Phase 2 trial in Type 1 patients is due to commence next month and will be conducted at QPharm in Queensland, Australia. QPharm is a well- established clinical facility and uniquely placed to conduct this type of diabetes trial. The trial is a randomized, single-blinded trial which aims to assess the efficacy of TPM/Insulin. The results of this trial will be used to assist in obtaining an IND from the FDA. This will enable Phosphagenics to commence the next phase of its clinical development program for TPM/Insulin at the Joslin Diabetes Centre. It is anticipated that the U.S. portion of the study will start this year.

"We have gathered the appropriate positive data to progress our Phase 2 study to the treatment of patients with Type 1 diabetes, which is the ideal patient population to prove the efficacy of our TPM/Insulin," said Dr. Esra Ogru, Executive Vice President of Research and Development at P
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
5. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015   Royal Philips  (NYSE: ... Magnetic Resonance (MR) solutions to be showcased at the ... 23 rd Annual Meeting & Exhibition in ... Philips booth #301 will see the latest in ... increase clinical performance, enhance patient experience and provide economic ...
(Date:6/1/2015)... June 1, 2015 Novel t ... drive growth , says   GBI Research ... (NSCLC) treatment market will be driven primarily by the introduction ... treatment settings, which either replace or combine with generic chemotherapies. ... Non-Small Cell Lung Cancer Market to 2020 - ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Philips showcases MR research solutions designed to enable collaboration with partners at the ISMRM Annual Meeting 2Philips showcases MR research solutions designed to enable collaboration with partners at the ISMRM Annual Meeting 3New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ -- ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ... for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Medicine Technology:ScinoPharm to Invest in Tanvex Biologics 2ScinoPharm to Invest in Tanvex Biologics 3ScinoPharm to Invest in Tanvex Biologics 4ScinoPharm to Invest in Tanvex Biologics 5ScinoPharm to Invest in Tanvex Biologics 6PharmaVentures Appoints Paul Phull as Senior Director 2PharmaVentures Appoints Paul Phull as Senior Director 3PharmaVentures Appoints Paul Phull as Senior Director 4PharmaVentures Appoints Paul Phull as Senior Director 5PharmaVentures Appoints Paul Phull as Senior Director 6
(Date:6/1/2015)... 2015 "This milestone opens the doors ... previously able to buy and sell shares of our ... and also make recommendations to clients as they so ... to trade shares of our Company,” said Kris Finstad, ... requirements of OTCQB provides our investors greater confidence in ...
(Date:6/1/2015)... Pittsburgh, PA (PRWEB) June 01, 2015 ... this new development in breast cancer prevention. , A ... Health suggests that postmenopausal women with ductal carcinoma in ... cancer treatment and prevention. , The study (NSABP B-35/NRG ... those who completed the standard five-year treatment with tamoxifen ...
(Date:6/1/2015)... For years, facial plastic surgery demands ... like one would request a hairstyle, patients would use ... and more to illustrate their adaptation of choice. However, ... ushering in a new era of aesthetic envy – ... Rizk, MD, FACS notes that since the explosion of ...
(Date:6/1/2015)... There’s never a good time to be sick ... minor illnesses. , As of June 1, OSF HealthCare is ... care via the Internet. Patients throughout Illinois can access care ... “Everyone is busy. We know that getting in to see ... to make it easier,” said Jeffry Tillery, MD, Chief Transformation ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 June 1, ... of clinical journals in the areas of hospital medicine, ... announce that it has expanded upon its partnership with ... Hospital Medicine Practice, in a mobile application format ... tablets. , “We are very excited about the ...
Breaking Medicine News(10 mins):Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... Serena Gordon HealthDay Reporter , WEDNESDAY, May ... the drug lenalidomide can significantly lengthen the time that ... disease, either after having a stem cell transplant or ... studies is whether or not the improved "progression-free" survival ...
... today released a wide-ranging compendium of resources ... and secure sharing of health information. ... Policies in Practice for Health Information Sharingor ... for electronic health information sharing, including informed ...
... Infectious diseasesboth old and newcontinue to exact a devastating ... the world. Vaccines remain the best line of ... Stephen Johnston, researchers at Arizona State University,s Biodesign Institute, ... Texas Southwestern Medical Center are using clever functional screening ...
... -- The rate at which Americans are hospitalized for stroke ... According to the U.S. National Center for Health Statistics (NCHS), ... people during the 1990s but had decreased again to under ... there were still about 800,000 hospitalizations for stroke in 1989 ...
... support and limited pressure to achieve the ,thin and beautiful, ... a new study looking at five factors that may help ... the context of a society where discontent with appearance is ... the University of Arizona in the US, and colleagues is ...
... HealthDay Reporter , TUESDAY, May 8 (HealthDay News) ... atrial fibrillation face a 14 percent greater risk of ... report. The raised risk remained higher even when ... stroke, the study authors noted. "Previously, there was ...
Cached Medicine News:Health News:New Drug Shows Promise for Myeloma Patients 2Health News:New Drug Shows Promise for Myeloma Patients 3Health News:Markle releases new resources for health information sharing implementation 2Health News:Markle releases new resources for health information sharing implementation 3Health News:Advanced genetic screening method may speed vaccine development 2Health News:Advanced genetic screening method may speed vaccine development 3Health News:Advanced genetic screening method may speed vaccine development 4Health News:Rate of Hospitalizations for Stroke Has Declined in U.S. 2Health News:Self-worth needs to go beyond appearance 2Health News:Irregular Heartbeat Poses Greater Stroke Risk for Women Than Men 2
... and VersaStep™ PLUS Reposable system components for creating each ... radial expandable sleeve is packaged sterile together with either ... Insufflation and access needle is packaged non-sterile; 5 ... are packaged non-sterile; 5 mm, 7/8 mm, 10 ...
SURGISPIKE™ Single Use 5 mm Trocar. , ,Bladed Trocars are devices that contain a metal blade to gain access to the abdominal cavity....
... The complete line of Surgical Access ... ,The OnePort™ trocar system is actually ... be versatile, operationally flexible and clinically adaptive ... offering options in disposability and bladed or ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
Medicine Products: